http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016135262-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7f89aa0c64464ae1daf42210ede68cd1 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-185 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-131 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-131 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate | 2016-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3bfab4bc31b84b4e4bf02da6f69277ae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9286bc131f847c28ffa3fef4b1b10162 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_903ad68f2f6d2f0c11b5d465baee02a9 |
| publicationDate | 2016-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2016135262-A1 |
| titleOfInvention | No donors for the treatment of impaired tissue perfusion |
| abstract | The invention relates to the field of medicine and particularly to the use of amino-C 2 -C 6 -alkyl nitrates or amino-C 2 -C 4 -alkyl nitrates or the pharmaceutically acceptable salt thereof for the treatment and prophylaxis of a chronic disease or condition associated with impaired tissue or organ perfusion. More particularly the invention provides novel treatment options for micro- and/or macro-vascular diseases selected from the group of diseases associated with impaired capillary function, impaired muscular function, impaired skin function, impaired cartilage function, impaired myocardial function, impaired retinal function or impaired organ function caused by impairment of tissue and organ perfusion or by impairment of the regeneration of capillaries, arterioles or other vascular tissue. Examples of such diseases are diseases associated with impaired wound healing (including burning injuries), ulcers (e.g. diabetic foot ulcer), and specifically severe peripheral artery disease including critical limb ischaemia in patients with or without type 2 diabetes, Moyamoya disease or metabolic disorders leading to vascular dysfunction. The invention also relates to the use of said amino-alkyl nitrates and the pharmaceutically acceptable salt thereof in the form of an extended release composition or in the form of skin patches. The most preferred amino-alkyl nitrate in accordance with the invention is 2-aminoethyl nitrate or its tosylate salt. |
| priorityDate | 2015-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 188.